Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing.

ABSTRACT:

Background

Tumor mutation burden (TMB) has received considerable attention as a potential predictive biomarker for response to anticancer treatment with immune checkpoint inhibitors (ICIs), and has been increasingly incorporated into clinical practice. Currently, TMB is often determined with tissue biopsies using whole-exome sequencing (WES) or panel-based targeted sequencing. Meanwhile, liquid biopsies such as blood are actively investigated as alternative media, although there is currently no report of the performance of targeted sequencing in assessing TMB using pleural effusion (PE) specimens.

Methods

Thirty-two patients diagnosed with advanced non-small cell lung cancer (NSCLC) with associated PE were prospectively enrolled (NCT03546452). Cell-free DNA (cfDNA) from the

SUBMITTER: Yu Y 

PROVIDER: S-EPMC7867960 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature